Skip to main content
Glama

Monarch Initiative

by io.github.pipeworx-io

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed1 schema field changed
    • changedInput schema / properties / value / description
      Previous value: -"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\")."New value: +"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed (\"NEW YORK ST DORM AUTH\"), never the question's full noun phrase (\"NEW YORK ST DORM AUTH revenue bonds\"): the FIGI lookup matches instrument names, so trailing security-class words match nothing."
  2. First observed

TDQS

A4.7/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already declare readOnly/openWorld/idempotent, and the description adds substantial behavior: cascading through multiple lookup endpoints, graceful degradation if GLEIF/OpenFIGI are unavailable, explicit `unresolved` fields, `figi_candidates` on ambiguity, source-labelled identifiers, and non-US ISIN resolution. No contradiction with annotations.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is front-loaded with purpose and organized into supported types, and nearly every sentence earns its place. It is quite long and some sentences are dense multi-clause run-ons, so it is not maximally concise, but it remains scannable enough for an agent.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

For a tool with no output schema and only two parameters, the description covers input normalization, ambiguity behavior, enrichment failure modes, source attribution, and edge cases like non-equity instruments and ISIN mappings. An agent has what it needs to select and invoke the tool correctly in a wide range of situations.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema description coverage is 100%, so baseline is 3, but the description adds significant meaning: accepted input forms (ticker, CIK, ISIN, name), a strong exact-string instruction for issuer names, a warning against trailing security-class words, and brand vs generic drug examples. This clearly exceeds schema-only guidance.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description states a specific verb and resource: 'resolve a user-spoken NAME to the canonical/official identifiers other tools require as input.' It gives concrete example queries and explicitly distinguishes this from generic search/entity tools by framing it as the first step when a name needs to become an ID.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

It provides an explicit rule: 'Use FIRST whenever you have a name but need an ID.' It also details accepted input shapes per type and warns about unsupported bond-name phrasing. However, it does not name sibling alternatives or explicitly state when not to use this tool, so it stops short of a 5.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Monarch Initiative toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.7/5.0
Disambiguation4/5

Most tools have clear, distinct purposes, especially within the same domain (e.g., Polymarket betting tools each serve a specific function). However, the multiple data-querying tools (ask_pipeworx, ask_pipeworx_grounded, deep_research) could cause confusion despite detailed descriptions.

Naming Consistency3/5

Many tools follow a verb_noun snake_case pattern (e.g., bet_research, compare_entities), but there are exceptions like ai_visibility_check, forget, and suggest_questions. The mix of imperative verbs and descriptive phrases creates inconsistency.

Tool Count2/5

With 35 tools, the server feels overloaded. While each domain (biomedical, financial, betting) is covered extensively, the sheer number of tools likely overwhelms agents, and many tools could be merged or split into separate servers.

Completeness4/5

The tool set is comprehensive for its declared purpose, covering biomedical queries, company data, betting analysis, memory management, and more. Minor gaps exist (e.g., no tool to delete a bet, no write operations for biomedical data), but the breadth is impressive.

Resources